Skip to main content

Advertisement

Table 5 Inadequate empirical antimicrobial treatments regarding the acquisition and the aetiology

From: Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: a prospective cohort study

Community acquired (n = 23) Healthcare-related (n = 32)
Aetiology (main R) Empiric treatment Aetiology (main R) Empiric treatment
S. aureus CTX1 S. aureus (FqnR) CTX + LVX4
S. epidermidis(oxaR) CTX S. aureus (oxaR) AMX-CLV
S. epidermidis(oxaR) CTX S. epidermidis (oxaR) AMX-CLV
S. epidermidis(oxaR) AMX-CLV2 S. epidermidis (oxaR) AMX-CLV
S. pneumoniae Delayed S. epidermidis (oxaR) Delayed
Strep. viridans CIP3 S. epidermidis (oxaR) ERT5
Strep. viridans CIP S. epidermidis (oxaR) CIP
E. faecalis CTX S. epidermidis (oxaR) PIP-TAZ6 + AMK7
E. faecalis CIP + MET S. pneumoniae Delayed
E. faecalis Delayed S. pneumoniae Delayed
Rhodococcus equi CTX E. faecium (ampicilinR) ERT + AMK
E. coli (Amox-clav R) AMX-CLV E. faecalis CTX
E. coli (Fqn R) CIP E. faecalis CTX-AZT8
E. coli (Amox-clav R) AMX-CLV E. faecalis Delayed
E. coli (FQ R) CIP Corynebacterium spp. Delayed
E. coli Delayed E. coli (ESBL FqnR) CTX
E. coli Delayed E. coli (ESBL) CTX
E. coli (Amox-clav R) AMX-CLV E. coli (FQ R) CIP
E. coli (Amox-clav R) AMX-CLV E. coli Delayed
K. pneumoniae (Amox-clav R) AMX-CLV K. pneumoniae (ESBL) Delayed
Enterobacter spp. AMX-CLV K. pneumoniae VAN9
Citrobacter spp. AMX-CLV K. pneumoniae VAN
Bacteroides spp. Delayed Enterobacter spp. (cefotax FqnR) CTX + LVX
Enterobacter spp. CFZ10 + VAN
Enterobacter spp. Delayed
Enterobacter spp. (Pip-tazR) PIP-TAZ
Enterobacter spp. Delayed
P. aeruginosa (ceftazi R) CFZ
P. aeruginosa (ceftaz R) CFZ + VAN
P. aeruginosa (FQ R) CTX + LVX
P. aeruginosa (FQ R) CTX + LVX
Acrhomobacter spp VAN
Candida spp. AMX-CLV
  1. 1 CTX cefotaxime, 2 AMX-CLV amoxicillin-clavulanic, 3 CIP ciprofloxacin, 4 LVX levofloxacin, 5 ERT ertapenem, 6 PIP-TAZ piperacilin-tazobactam, 7 AMK amikacin, 8 AZT azytromicin, 9 VAN vancomycin, 10 CFZ ceftazidime.